Hepavue
Hepavue

About

Over 2 billion people — more than a quarter of the world population — have asymptomatic chronic liver disease. Today, the needle biopsy remains the only diagnostic option. This method is fraught with disadvantages. It is expensive, painful, resource-intensive, samples only a tiny part of the liver and carries a bleeding/mortality risk. As such it is unsuitable for mass screening.

This shortcoming — coupled with liver diseases progressing silently — results in 70% of patients going unnoticed until terminal stage (cirrhosis). Hepavue has developed the world’s first proprietary virtual liver biopsy which will make liver disease diagnosis affordable, painless, safe and more accessible. Our technology will prevent avoidable cases of liver cancer, transplantations and deaths.

25%

of the world have
asymptomatic
early stage MAFLD*

*metabolic-dysfunction Associated Fatty liver Disease

+100M

individuals develop
inflammation
and progress*

*30M in EU & US alone

70%

first diagnosed
at terminal stage

 

A new paradigm for liver health management

Hepavue is not just developing a technology; we are leading a transformation in liver health management. Through timely and proactive care, we will drastically reduce the prevalence of terminal liver diseases, moving us closer to a world where it is an exception rather than a common fate.

Benign
liver steatosis

No liver signal

Progressive
liver disease

Strong liver signal

Product

Hepavue combines molecular tracers and AI-based medical imaging technology to offer accurate and early detection of progressive liver diseases. This first-in-class solution replaces traditional invasive biopsies, offering a safer, and more cost-effective alternative. By detecting signs of progressive liver disease early on, we enable immediate management strategies – potentially saving millions of lives in the process. Further, our technology enables personalized assessment of therapeutic responses, ensuring tailored and effective care.

First-in-class
with robust entry barriers

Unmatched
diagnostic accuracy

Rapid elimination
through kidney filtration

R&D Pipeline

Team

Hepavue

Maxime Nachit MD, PhD
CEO & Co-Founder

Hepavue

Hilde Revets MSc, PhD
Chief Development Officer
(ad interim)

Hepavue

Gaby El Alam MSc, Ir
Lead Engineer & Co-Founder

Hepavue

Sam Voccia MSc, PhD
Co-Founder, Board member and Strategic advisor

Hepavue

Ludovic Wouters MSc, PhD
Co-Founder, Board member and Strategic advisor

Scientific
Advisory
Board

Prof. Isabelle Leclercq MD, PhD
Professor at UCLouvainHepatologist & Head of Hepatology Laboratory at UCLouvain (Brussels, Belgium)

Prof. Yves Horsmans MD, PhD
Professor at UCLouvainHepatologist & Chair of Internal Medicine Department at University Hospital Saint-Luc (Brussels, Belgium)

Prof. Renaud Lhommel MD
Professor at UCLouvainNuclear Physician & Head of Nuclear Medicine Department at University Hospital Saint-Luc (Brussels, Belgium)

Prof. Bernard Van Beers MD, PhD
Professor at Université de ParisRadiologist & Head of Imaging Biomarker Laboratory at INSERM (Paris, France)

Dr. Alexis Broisat MSc, PhD
Researcher at Université Grenoble-Alpes Nuclear Medicine Engineer and Senior Scientist at INSERM (Grenoble, France)

Prof. Sven Francque MD, PhD
Professor at Antwerp University Hospital Hepatologist & Head of Gastroenterology Department at UZA (Antwerp, Belgium)

Prof. Nick Devoodgt MSc, PhD
Professor at Vrije Universiteit Brussel (VUB) Research at cluster Imaging and Physical Sciences (BEFY) In vivo Cellular and Molecular Imaging laboratory (Brussels, Belgium)

Partners

Hepavue
Hepavue
Hepavue
Hepavue
Hepavue

About

Over 2 billion people — more than a quarter of the world population — have asymptomatic chronic liver disease. Today, the needle biopsy remains the only diagnostic option. This method is fraught with disadvantages. It is expensive, painful, resource-intensive, samples only a tiny part of the liver and carries a bleeding/mortality risk. As such it is unsuitable for mass screening.

This shortcoming — coupled with liver diseases progressing silently — results in 70% of patients going unnoticed until terminal stage (cirrhosis). Hepavue has developed the world’s first proprietary virtual liver biopsy which will make liver disease diagnosis affordable, painless, safe and more accessible. Our technology will prevent avoidable cases of liver cancer, transplantations and deaths.

25%

of the world have
asymptomatic
early stage MAFLD*

*metabolic-dysfunction Associated Fatty liver Disease

+100M

individuals develop
inflammation
and progress*

*30M in EU & US alone

70%

first diagnosed
at terminal stage

 

A new paradigm for liver health management

Hepavue is not just developing a technology; we are leading a transformation in liver health management. Through timely and proactive care, we will drastically reduce the prevalence of terminal liver diseases, moving us closer to a world where it is an exception rather than a common fate.

Benign
liver steatosis

No liver signal

Progressive
liver disease

Strong liver signal

Product

Hepavue combines molecular tracers and AI-based medical imaging technology to offer accurate and early detection of progressive liver diseases. This first-in-class solution replaces traditional invasive biopsies, offering a safer, and more cost-effective alternative. By detecting signs of progressive liver disease early on, we enable immediate management strategies – potentially saving millions of lives in the process. Further, our technology enables personalized assessment of therapeutic responses, ensuring tailored and effective care.

First-in-class
with robust entry barriers

Unmatched
diagnostic accuracy

Rapid elimination
through kidney filtration

R&D Pipeline

Team

Hepavue

Maxime Nachit MD, PhD
CEO & Co-Founder

Hepavue

Gaby El Alam MSc, Ir
Lead Engineer & Co-Founder

Hepavue

Ludovic Wouters MSc, PhD
Co-Founder, Board member and Strategic advisor

Hepavue

Hilde Revets MSc, PhD
Chief Development Officer
(ad interim)

Hepavue

Sam Voccia MSc, PhD
Co-Founder, Board member and Strategic advisor

Scientific
Advisory
Board

Prof. Isabelle Leclercq MD, PhD
Professor at UCLouvainHepatologist & Head of Hepatology Laboratory at UCLouvain (Brussels, Belgium)

Prof. Yves Horsmans MD, PhD
Professor at UCLouvainHepatologist & Chair of Internal Medicine Department at University Hospital Saint-Luc (Brussels, Belgium)

Prof. Renaud Lhommel MD
Professor at UCLouvainNuclear Physician & Head of Nuclear Medicine Department at University Hospital Saint-Luc (Brussels, Belgium)

Prof. Bernard Van Beers MD, PhD
Professor at Université de ParisRadiologist & Head of Imaging Biomarker Laboratory at INSERM (Paris, France)

Dr. Alexis Broisat MSc, PhD
Researcher at Université Grenoble-Alpes Nuclear Medicine Engineer and Senior Scientist at INSERM (Grenoble, France)

Prof. Sven Francque MD, PhD
Professor at Antwerp University Hospital Hepatologist & Head of Gastroenterology Department at UZA (Antwerp, Belgium)

Prof. Nick Devoodgt MSc, PhD
Professor at Vrije Universiteit Brussel (VUB) Research at cluster Imaging and Physical Sciences (BEFY) In vivo Cellular and Molecular Imaging laboratory (Brussels, Belgium)

Partners

Hepavue
Hepavue
Hepavue
Hepavue
Hepavue